Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation

Laryngoscope

Volumn 126, Issue 12, 2016, Pages 2733-2738

  Platek, Alexis J ^a   Jayaprakash, Vijayvel ^a   Merzianu, Mihai ^a   Platek, Mary E ^a   Cohan, David M ^a   Hicks, Wesley L ^a   Marimuthu, Sathiya P ^a   Winslow, Timothy B ^a   Gupta, Vishal ^a   Arshad, Hassan ^a   Kuriakose, Moni A ^a   Dibaj, Shiva ^a   Marshall, James R ^a   Reid, Mary E ^a   Warren, Graham W ^b   Singh, Anurag K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

base of tongue; human papillomavirus; nicotine; squamous cell cancer of the head and neck; Tobacco

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; SMOKING CESSATION; SQUAMOUS CELL CARCINOMA; WART VIRUS; COMPLICATION; KAPLAN MEIER METHOD; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SMOKING CESSATION;

EID: 84978418239     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.26083     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
2. Society AC. Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015.
3. Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 2004;31:726–733.
4. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009;15:6758–6762.
5. Cleveland JL, Junger ML, Saraiya M, Markowitz LE, Dunne EF, Epstein JB. The connection between human papillomavirus and oropharyngeal squamous cell carcinomas in the United States: implications for dentistry. J Am Dent Assoc 2011;142:915–924.
6. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services; 2014.
7. Farshadpour F, Kranenborg H, Calkoen EV, et al. Survival analysis of head and neck squamous cell carcinoma: influence of smoking and drinking. Head Neck 2011;33:817–823.
8. Meyer F, Bairati I, Fortin A, et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer 2008;122:1679–1683.
9. Shen GP, Xu FH, He F, et al. Pretreatment lifestyle behaviors as survival predictors for patients with nasopharyngeal carcinoma. PLoS One 2012;7:e36515.
10. Duffy SA, Ronis DL, McLean S, et al. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol 2009;27:1969–1975.
11. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012;30:2102–2111.
12. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98:441–450.
13. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35.
14. Warren GW, Kasza KA, Reid ME, Cummings KM, Marshall JR. Smoking at diagnosis and survival in cancer patients. Int J Cancer 2013;132:401–410.
15. Warren GW, Marshall JR, Cummings KM, et al. Automated tobacco assessment and cessation support for cancer patients. Cancer 2014;120:562–569.
16. Dobson Amato KA, Hyland A, Reed R, et al. Tobacco cessation may improve lung cancer patient survival. J Thorac Oncol 2015;10:1014–1019.
17. Platek ME, McCloskey SA, Cruz M, et al. Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Head Neck 2013;35:684–688.
18. Fung-Kee-Fung SD, Hackett R, Hales L, Warren G, Singh AK. A prospective trial of volumetric intensity-modulated arc therapy vs conventional intensity modulated radiation therapy in advanced head and neck cancer. World J Clin Oncol 2012;3:57–62.
19. Dahlstrom KR, Calzada G, Hanby JD, et al. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer 2013;119:81–89.
20. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92:805–813.
21. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003;104:336–344.
22. Ihloff AS, Petersen C, Hoffmann M, Knecht R, Tribius S. Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy. Oral Oncol 2010;46:705–711.
23. Ang KK, Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 2012;22:128–142.
24. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010;16:1226–1235.
25. Worsham MJ, Stephen JK, Chen KM, et al. Improved survival with HPV among African Americans with oropharyngeal cancer. Clin Cancer Res 2013;19:2486–2492.
26. Sobus SL, Warren GW. The biologic effects of cigarette smoke on cancer cells. Cancer 2014;120:3617–3626.
27. Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol 2014;15:e568–e580.
28. Vaporciyan AA, Merriman KW, Ece F, et al. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. Ann Thorac Surg 2002;73:420–425; discussion 425–426.
29. Mason DP, Subramanian S, Nowicki ER, et al. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study. Ann Thorac Surg 2009;88:362–370; discussion 370–371.
30. Kuri M, Nakagawa M, Tanaka H, Hasuo S, Kishi Y. Determination of the duration of preoperative smoking cessation to improve wound healing after head and neck surgery. Anesthesiology 2005;102:892–896.
31. Sardari Nia P, Weyler J, Colpaert C, Vermeulen P, Marck EV, Schil PV. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer 2005;47:351–359.
32. van der Voet JC, Keus RB, Hart AA, Hilgers FJ, Bartelink H. The impact of treatment time and smoking on local control and complications in T1 glottic cancer. Int J Radiat Oncol Biol Phys 1998;42:247–255.
33. Bjarnason GA, Mackenzie RG, Nabid A, et al. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys 2009;73:166–172.
34. McCloskey SA, Jaggernauth W, Rigual NR, et al. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009;32:587–591.
35. Alberg AJ, Worley ML, Tooze JA, et al. The validity of self-reported recent smoking in head and neck cancer surgical patients. Otolaryngol Head Neck Surg 2015;153:990–995.
36. Warren GW, Arnold SM, Valentino JP, et al. Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiother Oncol 2012;103:45–48.
37. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823–829.
38. Hanna N, Mulshine J, Wollins DS, Tyne C, Dresler C. Tobacco cessation and control a decade later: American Society of Clinical Oncology policy statement update. J Clin Oncol 2013;31:3147–3157.
39. Toll BA, Brandon TH, Gritz ER, et al. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res 2013;19:1941–1948.
40. Ostroff JS, Goffin JR, Khuri FR, Warren GW. Perspective on the National Comprehensive Cancer Network's Clinical Practice Guidelines for Smoking Cessation. J Oncol Pract 2016;12:55–58.
41. Warren GW, Marshall JR, Cummings KM, et al. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. J Thorac Oncol 2013;8:543–548.
42. Warren GW, Marshall JR, Cummings KM, et al. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. J Oncol Pract 2013;9:258–262.
43. Peters EN, Torres E, Toll BA, et al. Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. J Clin Oncol 2012;30:2869–2875.